EP3624790A1 - Novel dosage principle for drugs useful for treating neoplastic diseases - Google Patents
Novel dosage principle for drugs useful for treating neoplastic diseasesInfo
- Publication number
- EP3624790A1 EP3624790A1 EP18722638.6A EP18722638A EP3624790A1 EP 3624790 A1 EP3624790 A1 EP 3624790A1 EP 18722638 A EP18722638 A EP 18722638A EP 3624790 A1 EP3624790 A1 EP 3624790A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable derivative
- neoplasms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 33
- 230000001613 neoplastic effect Effects 0.000 title claims description 33
- 201000010099 disease Diseases 0.000 title claims description 29
- 239000003814 drug Substances 0.000 title claims description 23
- 229940079593 drug Drugs 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 337
- 150000003839 salts Chemical class 0.000 claims abstract description 164
- 238000001802 infusion Methods 0.000 claims description 80
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 238000011282 treatment Methods 0.000 claims description 44
- 238000001990 intravenous administration Methods 0.000 claims description 29
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 210000002381 plasma Anatomy 0.000 claims description 16
- 230000036470 plasma concentration Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 4
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 201000009047 Chordoma Diseases 0.000 claims description 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 2
- 208000007842 Fibroepithelial Neoplasms Diseases 0.000 claims description 2
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 2
- 201000005618 Glomus Tumor Diseases 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 208000006050 Hemangiopericytoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 208000010423 Lymphatic Vessel Tumors Diseases 0.000 claims description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 208000010153 Mesonephroma Diseases 0.000 claims description 2
- 208000000811 Mesothelial Neoplasms Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 208000031675 Neoplasms, Adnexal and Skin Appendage Diseases 0.000 claims description 2
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims description 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
- 208000007871 Odontogenic Tumors Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000006288 Vascular Tissue Neoplasms Diseases 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 208000020719 chondrogenic neoplasm Diseases 0.000 claims description 2
- 208000012106 cystic neoplasm Diseases 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 210000000750 endocrine system Anatomy 0.000 claims description 2
- 201000006604 granular cell tumor Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 201000002222 hemangioblastoma Diseases 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 208000025095 immunoproliferative disease Diseases 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 2
- 208000022669 mucinous neoplasm Diseases 0.000 claims description 2
- 201000009368 muscle benign neoplasm Diseases 0.000 claims description 2
- 208000017708 myomatous neoplasm Diseases 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 201000004931 neurofibromatosis Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000007312 paraganglioma Diseases 0.000 claims description 2
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims description 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 208000016596 serous neoplasm Diseases 0.000 claims description 2
- 208000028467 sex cord-stromal tumor Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 208000010556 transitional cell papilloma Diseases 0.000 claims description 2
- 201000004420 transitional papilloma Diseases 0.000 claims description 2
- 208000029387 trophoblastic neoplasm Diseases 0.000 claims description 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 2
- 208000025443 tumor of adipose tissue Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 201000011531 vascular cancer Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 4
- 229940125898 compound 5 Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- NIPZLALJRAHABJ-IBGZPJMESA-N (2s)-2,6-diamino-n-[4-[2-[2-[4-(2-cyanoethylamino)-1,2,5-oxadiazol-3-yl]benzimidazol-1-yl]acetyl]phenyl]hexanamide Chemical compound C1=CC(NC(=O)[C@@H](N)CCCCN)=CC=C1C(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1NCCC#N NIPZLALJRAHABJ-IBGZPJMESA-N 0.000 description 28
- 239000012458 free base Substances 0.000 description 16
- 231100000682 maximum tolerated dose Toxicity 0.000 description 16
- 230000035487 diastolic blood pressure Effects 0.000 description 11
- 230000035488 systolic blood pressure Effects 0.000 description 11
- LSFOZQQVTWFMNS-UHFFFAOYSA-N avanbulin Chemical compound C1=CC(N)=CC=C1C(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1NCCC#N LSFOZQQVTWFMNS-UHFFFAOYSA-N 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010021036 Hyponatraemia Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 5
- 108091022875 Microtubule Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- -1 2 hour i.v. infusion Chemical compound 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FIWVAISHBIQYOU-RWPZCVJISA-N 1-(4-amino-1,2,5-oxadiazol-3-yl)-n-[(e)-[4-[(3-methylphenyl)methoxy]phenyl]methylideneamino]-5-(piperidin-1-ylmethyl)triazole-4-carboxamide Chemical compound CC1=CC=CC(COC=2C=CC(\C=N\NC(=O)C3=C(N(N=N3)C=3C(=NON=3)N)CN3CCCCC3)=CC=2)=C1 FIWVAISHBIQYOU-RWPZCVJISA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- JDQDSEVNMTYMOC-UHFFFAOYSA-N 3-methylbenzenesulfonic acid Chemical compound CC1=CC=CC(S(O)(=O)=O)=C1 JDQDSEVNMTYMOC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
- SIVVHUQWDOGLJN-UHFFFAOYSA-N ethylsulfamic acid Chemical group CCNS(O)(=O)=O SIVVHUQWDOGLJN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- HLIBNTOXKQCYMV-UHFFFAOYSA-N propylsulfamic acid Chemical compound CCCNS(O)(=O)=O HLIBNTOXKQCYMV-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000002553 single reaction monitoring Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a new dosage principle for drugs useful for treating neoplastic diseases. More particular, the present invention relates to a new dosage regimen for the anti-cancer drug
- BAL27862 and pro-drugs thereof in particular BAL101553 and pharmaceutically acceptable salts of said drug and pro-drugs.
- Microtubules are one of the components of the cell cytoskeleton and are composed of heterodimers of alpha and beta tubulin. Agents that target microtubules are among the most effective cytotoxic chemotherapeutic agents having a broad spectrum of activity.
- Microtubule destabilising agents e.g. the vinca-alkaloids such as vincristine, vinblastine and vinorelbine
- microtubule stabilising agents e.g. the taxanes such as paclitaxel, docetaxel
- solid tumors including breast, lung and prostate cancer.
- WO2004/103994 describes a recently discovered class of microtubule destabilising agents.
- One compound falling within this class known as BAL27862 (referred to herein as the compound of formula I- A), and shown in WO2004/103994 under Example 58, has the structure and chemical name given below:
- WO2011/012577 discloses pro-drugs of the compounds disclosed in WO2004/103994.
- One compound known as BAL101553 (referred to herein as the compound of formula I-B) and shown in
- WO2011/012577 under Example 1 has the chemical name and structure given below:
- the compound of formula I-B is a highly water-soluble pro-drug of the compound of formula I-A which forms the compound of formula I-A in- vivo following administration.
- the compound of formula I-B is particularly advantageously used in the form of a pharmaceutically acceptable acid addition salt, like a hydrochloride salt thereof, in particular in the form of its dihydrochloride salt. These compounds have been shown to arrest tumor cell proliferation and induce apoptosis.
- the compound of formula I-A and the pro-drug of formula I-B have demonstrated antitumor activity across a broad panel of experimental tumor models.
- WO2015/173341 describes a dosage regime in which compounds of formula I and pharmaceutically acceptable derivatives thereof as described therein are administered to patients intravenously at a specific dosage frequency and a specific treatment cycle at a dose being below the maximum tolerated dose defined for said dosage frequency and treatment cycle, but providing at least the same exposure of the tissue of the cancer from which said cancer patient is suffering, to said drug as provided by the maximum tolerated dose (MTD) at the same dosage frequency and treatment cycle.
- MTD maximum tolerated dose
- phase l/2a trial results of the compound of formula I-B were presented at the ASCO Annual Meeting June 3-7, 2016 in a poster entitled "Phasel/2a trial of intravenous BAL101553, a novel tumor checkpoint controller in advanced solid tumors" (2016-ASCO Poster Abstract 2525).
- the compound of formula I-B was administered to patients by 2-hour infusion on study days 1, 8 and 15, q28 days.
- a recommended phase 2 dose of 30mg/m 2 was defined.
- the poster also reported dose-dependent vascular effects that were dose-limiting and related to peak drug concentration (C max ).
- C max peak drug concentration
- the present invention relates in a first aspect to a compound of formula I
- R represents phenyl or pyridinyl
- phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, hydroxyl, amino, lower alkylamino, lower dialkylamino, acetylamino, halogen and nitro, preferably selected from lower alkyl, lower alkoxy, amino, acetylamino, halogen and nitro;
- pyridinyl is optionally substituted by amino or halogen
- R 1 represents hydrogen or cyano-lower alkyl
- said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient, preferably by continuous infusion, over a period of at least about 8 hours, and wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 45mg/m 2 of the dihydrochloride salt of the compound formula I-B.
- the invention provides use of a compound of formula I or pharmaceutically acceptable derivative thereof, which pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, in the manufacture of a medicament for the treatment of a neoplastic disease in a patient, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient, preferably by continuous infusion, over a period of at least about 8 hours, and wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 45mg/m 2 of the dihydrochloride salt of the compound of formula I-B.
- the invention provides a method of treating a neoplastic disease in a patient comprising administering to said patient a compound of formula I or pharmaceutically acceptable derivative thereof, which pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient, preferably by continuous infusion, over a period of at least about 8 hours, and wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 45mg/m 2 of the dihydrochloride salt of the compound of formula I-B.
- Figure 1 shows the C max results of BAL27862 from patients administered with the dihydrochloride salt of BAL101553 as a 2-hour intravenous infusion and patients administered with the dihydrochloride salt of BAL101553 as a 48-hour intravenous infusion.
- the box and whiskers plots the box represents 25 th and 75 th percentiles (interquartile range, IQR), inside the box the solid line is the arithmetic mean and the dashed line is the median; the whiskers represent 1.5 x IQR or min/max range; individual data points outside the IQR whiskers are shown as individual dot outliers.
- IQR interquartile range
- Figure 2 shows the Area Under the Curve (AUC) results of BAL27862 from patients administered with the dihydrochloride salt of BAL101553 as a 2-hour intravenous infusion and patients administered with the dihydrochloride salt of BAL101553 as a 48-hour intravenous infusion.
- the box and whiskers plots the box represents 25 th and 75 th percentiles (interquartile range, IQR), inside the box the solid line is the arithmetic mean and the dashed line is the median; the whiskers represent 1.5 x IQR or min/max range; individual data points outside the IQR whiskers are shown as individual dot outliers.
- IQR interquartile range
- SBP systolic blood pressure
- DBP diastolic blood pressure
- SBP systolic blood pressure
- DBP diastolic blood pressure
- Figure 5 shows a comparison of the C max results of BAL27862 from patients administered with the dihydrochloride salt of BAL101553 as a 16 mg and 20 mg daily oral administration and patients administered with the dihydrochloride salt of BAL101553 as a 70 mg/m 2 and 90 mg/m 2 48-hour intravenous infusion.
- the box and whiskers plots the box represents 25 th and 75 th percentiles
- IQR interquartile range
- the solid line is the arithmetic mean and the dashed line is the median; the whiskers represent 1.5 x IQR or min/max range; individual data points outside the IQR whiskers are shown as individual dot outliers.
- Figure 6 shows a comparison of the Area Under the Curve (AUC) results of BAL27862 from patients administered with the dihydrochloride salt of BAL101553 as a 16 mg and 20 mg daily oral administration and patients administered with the dihydrochloride salt of BAL101553 as a 70 mg/m 2 and 90 mg/m 2 48- hour intravenous infusion.
- the box and whiskers plots the box represents 25 th and 75 th percentiles (interquartile range, IQR), inside the box the solid line is the arithmetic mean and the dashed line is the median; the whiskers represent 1.5 x IQR or min/max range; individual data points outside the IQR whiskers are shown as individual dot outliers.
- Preferred compounds of formula I include those wherein R and R 1 are defined as follows:
- R and R 1 are defined as follows: or pharmaceutically acceptable derivatives thereof.
- An especially preferred compound is the compound of formula I-A or pharmaceutically acceptable derivative thereof:
- pharmaceutically acceptable derivatives of compounds of formula I relates to pharmaceutically acceptable salts, pro-drugs and pharmaceutically acceptable salts of pro-drugs thereof.
- references to compounds of formula I and pharmaceutically acceptable derivatives thereof includes solvates and complexes (including hydrates) thereof as well as any polymorphs of the foregoing.
- references to compounds of formula I and pharmaceutically acceptable derivatives thereof also includes all optical, geometric and tautomeric isomers where possible.
- Salts are preferably acid addition salts. Salts are formed, preferably with organic or inorganic acids, from compounds of formula I or pharmaceutically acceptable derivatives thereof with a basic nitrogen atom, especially the pharmaceutically acceptable salts. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
- Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane- sulfonic acid, 2-hydroxyethanesulfonic acid, ethane- 1 ,
- the compound according to the invention may be administered in the form of a pro-drug, including pharmaceutically acceptable salts thereof, which is broken down in the human to give a compound of the formula I.
- pro-drugs include in vivo hydrolysable esters and amides of a compound of the formula I.
- Particular pro-drugs considered are ester and amides of naturally occurring amino acids and ester or amides of small peptides, in particular small peptides consisting of up to five, preferably two or three amino acids as well as esters and amides of pegylated hydroxy acids, preferably hydroxy acetic acid and lactic acid.
- Pro-drug esters are formed from the acid function of the amino acid or the C terminal of the peptide and suitable hydroxy group(s) in the compound of formula I.
- Pro-drug amides are formed from the amino function of the amino acid or the N terminal of the peptide and suitable carboxy group(s) in the compound of formula I, or from the acid function of the amino acid or the C terminal of the peptide and suitable amino group(s) in the compound of formula I.
- the pro-drug amides are formed from the amino group(s) present within the R group of formula I. More preferably, the prodrug is an amide formed from an amino group present within the R group of the compound of formula I as defined above and the carboxy group of glycine, alanine or lysine.
- the compound of formula I is in the form of a pro-drug selected from the compounds of the following formulae and pharmaceutically acceptable salts thereof:
- a pharmaceutically acceptable salt thereof preferably a hydrochloride salt, most preferably a dihydrochloride salt.
- pro-drugs of the invention may be prepared as described for example in WO2012/098207 on pages 40 to 42, which are hereby incorporated by reference.
- the dihydrochloride salt of the compound of formula I-B is administered at a dosage level of at least about 45mg/m 2 . In other embodiments of the invention higher dosage levels are used.
- the 10 dosage level of the dihydrochloride salt of the compound of formula I-B may be at least about 60mg/m 2 , at least about 70mg/m 2 , at least about 100mg/m 2 , or even at least about 140mg/m 2 . In some cases the dosage level of the dihydrochloride salt of compound of formula I-B may be about 200mg/m 2 .
- ranges of dosage levels of the dihydrochloride salt of compound of formula I-B include about 45mg/m 2 to about 200mg/m 2 , about 70mg/m 2 to about 200mg/m 2 , about 45 mg/m 2 to about 140 mg/m 2 , about
- the dosage level of the dihydrochloride salt of the compound of formula I-B may be up to about
- 60mg/m 2 up to about 70mg/m 2 , up to about lOOmg/m 2 , up to about 140mg/m 2 or up to about 200mg/m 2.
- the compound of formula I or pharmaceutically acceptable derivative thereof is administered at the molar 20 equivalents of the given dosage amounts for the dihydrochloride salt of the compound of formula I-B.
- the molar mass of the dihydrochloride salt of the compound of formula I-B is 588.49g/mol (C26H29N9O3 x 2HC1) based on IUPAC2009 atomic weights.
- the compound of formula I-B has the CAS registry number 1387574-54-0. Converting the above dosage amounts for the dihydrochloride salt of the
- the compound of formula I or pharmaceutically acceptable derivative thereof is administered at a dosage level of at least about 0.076moles/m 2 .
- higher dosage levels are used.
- the dosage level may be at least about 0.102moles/m 2 , at least about 0.119moles/m 2 , at least about 0.170moles/m 2 , or even at least about 0.238moles/m 2 .
- the dosage level may be about 0.340moles/m 2 .
- ranges of dosage levels include about 0.076moles/m 2 to about 0.340moles/m 2 , about 0.119moles/m 2 to about 5 0.340moles/m 2 , about 0.076moles/m 2 to about 0.238moles/m 2 , about 0.119moles/m 2 to about
- the dosage level of the dihydrochloride salt of the compound of formula I-B may be up to about up to about 0.102moles/m 2 , up to about 0.119moles/m 2 , up to about 0.170moles/m 2 , up to about 0.238moles/m 2 or up to about 0.340moles/m 2 .
- Dosages of the dihydrochloride salt of the compound of formula I-B may be expressed in terms of amounts of the free base of the compound of formula I-B.
- the molar mass of the free base of the compound of formula I-B is 515.58g/mol.
- 45mg/m 2 of the dihydrochloride salt of the compound of formula I-B is approximately equal to 39.4mg/m 2 of the free base of the compound of formula I-B.
- Dosages of the dihydrochloride salt of the compound of formula I-B may be expressed in terms of 25 amounts of the free base of the compound of formula I-A.
- compound of formula I-A is 387.40g/mol.
- 45mg/m 2 of the dihydrochloride salt of the compound of formula I-B is approximately equal to 29.6mg/m 2 of the free base of the compound of formula I-A.
- 60mg/m 2 of the dihydrochloride salt of the compound of formula I-B is approximately equal to
- 200mg/m 2 of the dihydrochloride salt of the compound of formula I-B is 35 approximately equal to 131.7mg/m 2 of the free base of the compound of formula I-A.
- the indicated surface area represents the body surface area (BSA), which can be determined by methods generally known in the art, e.g. by measurement or calculation.
- BSA body surface area
- Doses for chemotherapy treatment are usually calculated according to BSA, which is determined by using a nomogram scale or by using a BSA calculator. Once the BSA is determined, it is multiplied by the amount of drug specified in the regimen to give the total dose of drug to be administered (Chu and DeVita, Physicians' Cancer Chemotherapy Drug Manual 2013, Jones & Bartlett Learning).
- BSA(m 2 ) W A 0.425 * ⁇ ⁇ " 0.725 * 0.007184, where W is weight in kg and H is height in cm (Govindan and Morgensztern, Washington Manual of Oncology).
- W weight in kg
- H height in cm
- a dose of 45mg/m 2 for men would typically require a dose of about 86mg.
- a dose of 70mg/m 2 for men would typically require a dose of about 134mg.
- a dose of 140mg/m 2 for men would typically require a dose of about 267mg.
- a dose of 45mg/m 2 for women would typically require a dose of about 77mg.
- a dose of 70mg/m 2 for women would typically require a dose of about 120mg.
- a dose of 140mg/m 2 for women would typically require a dose of about 239mg.
- the dose of the compound of formula I or derivative thereof, which derivative may be the compound of formula I-B, is administered over a period of at least about 8 hours, preferably over a period of at least about 24 hours, more preferably over a period of at least about 48 hours. In some cases the administration may be over a period of about 120 hours. Examples of ranges of administration periods include about 8 to about 120 hours, about 24 hours to about 120 hours, about 48 hours to about 120 hours, about 24 hours to about 64 hours, or about 48 hours to about 64 hours. In one embodiment the dose is administered over a period of about 48 hours.
- the compound of formula I or pharmaceutically acceptable derivative thereof is administered intravenously over a prescribed period of time, suitably continuously and preferably substantially without interruption, e.g. the period of administration does not include an interruption of more than 30 minutes and/or a cumulative interruption of more than 10%> of the total of period of administration.
- the compound of formula I or pharmaceutically acceptable derivative thereof is administered by continuous infusion.
- Administration by continuous infusion involves intravenous administration of the medication without interruption over the prescribed period of time. This can mean that the rate of infusion does not vary by more than 50%> from the mean flow rate over the duration of administration.
- the administration is usually by means of a pump which provides the patient with intravenous administration of the medicament at a generally constant rate. Suitable devices are well-known in the art and may be mechanical or electrical.
- the devices are portable by the patient and can be worn by the patient, e.g. to provide minimal interference in daily life.
- the pump may be attachable to the patient's body e.g. via a cannula.
- An administration tube or other conduit connects the pump to the infusion site on the patient's body.
- the elastomeric infusion pump is one type of mechanical device, which comprises an elastomeric reservoir in which the solution to be administered is placed, and a flow restrictor system located in the administration tube. The combination of both the pressure generated by the filled reservoir and the flow restrictor provides a constant flow rate, independently of gravity.
- non- electronic devices are pumps using a spring (e.g. a coil shaped spring).
- Electronic pumps are also in use and generally utilize syringes or cartridges as reservoirs for the infusion solution that is administered to the patient.
- Thiveaud et al., European Journal of Hospital Pharmacy Practice, P 2/2005 compare the performance of some elastomeric devices.
- elastomeric pumps are preferred as they are generally smaller and less obtrusive than electrical pumps.
- the dose of the compound of formula I or derivative thereof, which derivative may be the compound of formula I-B is administered by continuous infusion over a period of at least about 24 hours, preferably over a period of at least about 48 hours.
- the administration by continuous infusion may be over a period of about 120 hours. Examples of ranges of administration periods for continuous infusion include about 24 hours to about 120 hours, about 48 hours to about 120 hours, about 24 hours to about 64 hours, or about 48 hours to about 64 hours.
- the dose is administered by continuous infusion over a period of about 48 hours.
- the compound of formula I or derivative thereof which may be the dihydrochloride salt of the compound of formula I-B, is administered according to a desired treatment cycle.
- the compound of formula I or derivative thereof will usually be administered at least once per week.
- there may be an administration pause every fourth week e.g. such that the patient receives treatment every week for three weeks and then no treatment in the fourth week.
- the treatment cycle may be once every two weeks or once every three weeks.
- example treatment cycles include the following:
- administrations For 48-hour administration / 28 day treatment cycle: administration on days 1, 8, 15, 22 (four administrations) .
- administration on day X means that administration commences on day X.
- the active ingredient can be in powder (e.g. lyophilized) form and reconstituted with a suitable diluent e.g. saline solution or Ringer lactate solution, preferably Ringer lactate solution, immediately prior to administration.
- a suitable diluent e.g. saline solution or Ringer lactate solution, preferably Ringer lactate solution
- the active ingredient may be initially reconstituted with saline solution or Ringer lactate solution and then diluted to the required concentration with Ringer lactate solution.
- the dosage volume can be for example from about 100ml to about 1000ml, e.g. at least about 100ml, e.g. up to about 1000ml.
- the dosage volume is from about 100ml to about 500ml, e.g. at least about 100ml, e.g. up to about 500ml.
- Other examples of dosage volumes are about 200ml to about 500ml, e.g. at least 200ml, e.g. up to 500ml.
- the dosage volume is about 240ml.
- solubility of the compound of formula I or pharmaceutical derivative thereof it may be desirable to use larger volumes with higher doses. Smaller volumes may require lower flow rates which may lead to inconsistencies in dosing as variability in the flow rate will lead to higher variability in dosing. For example we have found that a more reliable flow rate can be achieved with a volume of 240ml rather than 120ml over 48 hours. On the other hand we have also found that care needs to be taken with regard to the relative level of residual environmental impurities, which may become an issue when the concentration of active ingredient is low.
- the flow rate is determined by the dosage volume and the time period over which the dosage is administered.
- the flow rate may be about lml/hour to about 12ml/hour, e.g. 2.5ml/hour to about 12ml/hour, e.g. about 2.5ml/hour to about lOml/hour.
- the flow rate may be at least about lml/hour, e.g. at least about 2.5ml/hour, e.g. up to 12ml/hour, e.g. up to lOml/hour, e.g. less than 12ml/hour, e.g. less than 1 Oml/hour.
- a typical flow rate is about 5ml/hour.
- the invention provides a compound of formula I or pharmaceutically acceptable derivative thereof, which pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, for use in the treatment of a neoplastic disease in a patient, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient 10 over a period of at least about 24 hours, and wherein the dose of the compound of formula I or
- pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 45mg/m 2 of the dihydrochloride salt of the compound formula I-B.
- the invention provides a compound of formula I or pharmaceutically acceptable 15 derivative thereof, which pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, for use in the treatment of a neoplastic disease in a patient, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient by continuous infusion over a period of at least about 24 hours, and wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 20 45mg/m 2 of the dihydrochloride salt of the compound formula I-B.
- the invention provides a compound of formula I or pharmaceutically acceptable derivative thereof, which pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, for use in the treatment of a neoplastic disease in a patient, wherein said 25 compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient by continuous infusion over a period of at least about 24 hours, and wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 60mg/m 2 of the dihydrochloride salt of the compound formula I-B.
- the invention provides a compound of formula I or pharmaceutically acceptable derivative thereof, which pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, for use in the treatment of a neoplastic disease in a patient, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient by continuous infusion over a period of at least about 48 hours, and wherein the dose of the compound of
- the invention provides a compound of formula I or pharmaceutically acceptable derivative thereof, which pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, for use in the treatment of a neoplastic disease in a patient, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient 5 by continuous infusion over a period of at least about 24 hours, and wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 70mg/m 2 of the dihydrochloride salt of the compound formula I-B.
- the invention provides a compound of formula I or pharmaceutically acceptable 10 derivative thereof, which pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, for use in the treatment of a neoplastic disease in a patient, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient by continuous infusion over a period of at least about 48 hours, and wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 15 70mg/m 2 of the dihydrochloride salt of the compound formula I-B.
- the compound of formula I-B or pharmaceutically acceptable salt thereof preferably the dihydrochloride salt of the compound of formula I-B
- the compound of formula I-B or pharmaceutically acceptable salt thereof preferably the dihydrochloride salt of the compound of formula I-B
- the compound of formula I-B, or pharmaceutically acceptable salt thereof, 30 preferably the dihydrochloride salt of the compound of formula I-B is administered to the patient by continuous infusion over a period of at least about 24 hours and wherein the dose of the compound of formula I-B or pharmaceutically acceptable salt thereof is at least the molar equivalent of about 60mg/m 2 of the dihydrochloride salt of the compound formula I-B.
- the dihydrochloride salt of the compound of formula I-B is administered to the patient by continuous infusion over a period of at least about 24 hours and wherein the dose of the compound of formula I-B or pharmaceutically acceptable salt thereof is at least the molar equivalent of about 70mg/m 2 of the dihydrochloride salt of the compound formula I-B.
- the compound of formula I-B or pharmaceutically acceptable salt thereof preferably the dihydrochloride salt of the compound of formula I-B
- the compound of formula I-B or pharmaceutically acceptable salt thereof preferably the dihydrochloride salt of the compound of formula I-B
- the compound of formula I-B or pharmaceutically acceptable salt thereof preferably the dihydrochloride salt of the compound of formula I-B
- the compound of formula I-B or pharmaceutically acceptable salt thereof preferably the dihydrochloride salt of the compound of formula I-B
- the compound of formula I-B or pharmaceutically acceptable salt thereof preferably the dihydrochloride salt of the compound of formula I-B
- the compound of formula I-B or pharmaceutically acceptable salt thereof preferably the dihydrochloride salt of the compound of formula I-B
- I-A* means the compound of formula I-A or pharmaceutically acceptable derivative thereof
- I-B* means the compound of formula I-B or pharmaceutically acceptable salt thereof
- Embodiment 1 provides the compound of formula I-A or pharmaceutical derivative thereof for use in the treatment of a neoplastic disease in a patient, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient by continuous infusion over a period of about 24 hours, wherein the dose of the compound of formula I-A or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 45mg/m 2 of the dihydrochloride salt of the compound of formula I-B and wherein the dosage volume is about 100ml.
- Embodiment 49 provides the compound of formula I-B or pharmaceutically acceptable salt thereof, preferably the dihydrochloride salt thereof, for use in the treatment of a neoplastic disease in a patient, wherein said compound of formula I-B or pharmaceutically acceptable salt thereof is intravenously administered to said patient by continuous infusion over a period of about 24 hours, wherein the dose of the compound of formula I-B or pharmaceutically acceptable salt thereof is at least the molar equivalent of about 45mg/m 2 of the dihydrochloride salt of the compound of formula I-B and wherein the dosage volume is about 100ml.
- the mean increase in systolic blood pressure during administration compared to systolic blood pressure prior to administration may not be more than about 20mmHg.
- the mean increase in systolic blood pressure during administration compared to systolic blood pressure prior to administration may not be more than about 15mmHg.
- the mean increase in diastolic blood pressure during administration compared to diastolic blood pressure prior to administration may not increase by more than about 1 OmmHg.
- the mean increase in diastolic blood pressure during administration compared to diastolic blood pressure prior to administration may not increase by more than about 5mmHg.
- the patient's base line blood pressure in a sedentary state may be taken as the patient's blood pressure prior to administration.
- Blood pressure readings including base readings may be determined according to standard procedures (see for example Pickering and Stevens, How to measure and record blood pressure, Community Eye Health, 2013, 26(84), 76).
- the sample will usually be a random sample of at least 10 patients, preferably at least 100 patients.
- the mean increase in blood pressure will be determined during a clinical trial, in particular a phase 3 clinical trial.
- the compound of formula I or pharmaceutically acceptable derivative thereof may be administered to the patient such that the blood plasma concentration (C max ) of the compound of formula I (i.e. the active moiety, e.g. the compound of formula I-A) remains below about 450ng/ml.
- the compound of formula I or pharmaceutically acceptable derivative thereof may be administered to the patient such that the blood plasma concentration (C max ) of the compound of formula I (i.e. the active moiety, e.g. the compound of formula I-A) does not increase above about 300ng/ml.
- the compound of formula I or pharmaceutically acceptable derivative thereof may be administered to the patient such that the blood plasma concentration (C max ) of the compound of formula I (i.e. the active moiety, e.g. the compound of formula I-A) does not increase above about 250ng/ml.
- the compound of formula I or pharmaceutically acceptable derivative thereof may be administered at a dose such that the mean blood plasma concentration (C max ) of the compound of formula I (i.e. the active moiety, e.g. the compound of formula I-A) remains below about 450ng/ml.
- the compound of formula I or pharmaceutically acceptable derivative thereof may be administered at a dose such that the mean blood plasma concentration (C max ) of the compound of formula I (i.e. the active moiety, e.g. the compound of formula I-A) does not increase above about 300ng/ml.
- the compound of formula I or pharmaceutically acceptable derivative thereof may be administered at a dose such that the mean blood plasma
- concentration (C max ) of the compound of formula I i.e. the active moiety, e.g. the compound of formula I- A) does not increase above about 250ng/ml.
- the sample will usually be a random sample of at least 10 patients, preferably at least 100 patients.
- the mean increase in blood plasma concentration (C max ) will be determined during a clinical trial, in particular a phase 3 clinical trial.
- a further aspect of the invention provides a compound of formula I or pharmaceutical derivative thereof, which may be the dihydrochloride salt of the compound of formula I-B, for use in the treatment of a neoplastic disease in a patient, wherein said compound or pharmaceutically acceptable derivative thereof is intravenously administered to said patient, preferably by continuous infusion, over a period of more than 2 hours, and wherein the dose of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of about 45mg/m 2 of the dihydrochloride salt of the compound formula I-B and wherein the patient's blood plasma concentration (C max ) of the compound of formula I does not increase above about 450ng/ml.
- C max blood plasma concentration
- the patient's blood plasma concentration (C max ) of the compound of formula I does not increase above about 300ng/ml. In another embodiment the patient's blood plasma concentration (C max ) of the compound of formula I does not increase above about 250ng/ml.
- a further aspect of the invention provides a pharmaceutical composition for intravenous administration comprising the compound of formula I or pharmaceutically acceptable derivative thereof in an amount that is at least the molar equivalent of 160mg of the dihydrochloride salt of the compound of formula I-B, in saline solution and/or Ringer lactate solution, preferably Ringer lactate solution.
- pharmaceutical composition comprises the compound of formula I or pharmaceutically acceptable derivative thereof in an amount that is at least the molar equivalent 230mg of the dihydrochloride salt of the compound of formula I-B.
- the invention provides a method of preparing a pharmaceutical composition for intravenous administration, comprising the step of reconstituting an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 160mg of the dihydrochloride salt of the compound of formula I-B e.g. in saline solution and/or Ringer lactate solution, preferably Ringer lactate solution.
- the amount of the compound of formula I or pharmaceutically acceptable derivative thereof is at least the molar equivalent of 230mg of the dihydrochloride salt of the compound of formula I-B.
- the invention provides a method of preparing a pharmaceutical composition for intravenous administration, comprising the step of reconstituting an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 50mg of the dihydrochloride salt of the compound of formula I-B e.g. in saline solution and/or Ringer lactate solution, preferably Ringer lactate solution and the step of filling a pump for continuous infusion with the reconstituted compound of formula I or pharmaceutically acceptable derivative thereof.
- the method of preparing a pharmaceutical composition for intravenous administration comprises reconstituting an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 70mg of the dihydrochloride salt of the compound of formula I-B.
- the method of preparing a pharmaceutical composition for intravenous administration comprises reconstituting at least an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 11 Omg of the dihydrochloride salt of the compound of formula I-B.
- the method of preparing a pharmaceutical composition for intravenous administration comprises reconstituting an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 160mg of the dihydrochloride salt of the compound of formula I-B.
- the method of preparing a pharmaceutical composition for intravenous administration comprises reconstituting an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 230mg of the dihydrochloride salt of the compound of formula I-B.
- the invention provides a continuous infusion pump comprising a pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 50mg of the dihydrochloride salt of the compound of formula I-B, preferably in saline and/or Ringer lactate solution, preferably Ringer lactate solution.
- the pharmaceutical composition comprises an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 70mg of the dihydrochloride salt of the compound of formula I-B.
- the pharmaceutical composition comprises an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 11 Omg of the dihydrochloride salt of the compound of formula I-B. In another embodiment the pharmaceutical composition comprises an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 160mg of the dihydrochloride salt of the compound of formula I-B. In another embodiment the pharmaceutical composition comprises an amount of the compound of formula I or pharmaceutically acceptable derivative thereof that is at least the molar equivalent of 23 Omg of the dihydrochloride salt of the compound of formula I-B.
- the invention provides a kit for administering to a patient suffering from a neoplastic disease a compound of formula I or a pharmaceutically acceptable derivative thereof, which
- pharmaceutically acceptable derivative may be the dihydrochloride salt of the compound of formula I-B, comprising a sterile container comprising an amount of the compound of formula I or pharmaceutically derivative thereof that is at least the molar equivalent of 50mg of the dihydrochloride salt of the compound of formula I-B, preferably in powder (e.g. lyophilized) form, and a pump for continuous infusion, preferably an elastomeric pump.
- the kit may also include saline solution and/or Ringer lactate solution, preferably Ringer lactate solution, for reconstituting the compound of formula I or
- the sterile container comprises an amount of the compound of formula I or pharmaceutically derivative thereof that is at least the molar equivalent of 7 Omg of the dihydrochloride salt of the compound of formula I-B. In another embodiment the sterile container comprises an amount of the compound of formula I or pharmaceutically derivative thereof that is at least the molar equivalent of 11 Omg of the dihydrochloride salt of the compound of formula I-B. In another embodiment the sterile container comprises an amount of the compound of formula I or pharmaceutically derivative thereof that is at least the molar equivalent of 160mg of the dihydrochloride salt of the compound of formula I-B.
- the sterile container comprises an amount of the compound of formula I or pharmaceutically derivative thereof that is at least the molar equivalent of 23 Omg of the dihydrochloride salt of the compound of formula I-B.
- the kit may include a cannula and/or administration tube or other conuit for delivering the compound of formula I or pharmaceutically acceptable derivative thereof into the patient's body.
- the kit may also include instructions for reconstituting the compound of formula I or pharmaceutically acceptable derivative thereof to provide a dose corresponding to at least the required molar equivalent of the dihydrochloride salt of the compound of formula I-B and optionally for filling the pump with the reconstituted compound of formula I or pharmaceutically acceptable derivative thereof.
- treatment in the context of treating a neoplastic disease in a patient pertains generally to treatment and therapy in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the neoplastic disease, and includes a reduction in the rate of progress, a halt in the rate of progress, alleviation of symptoms of the neoplastic disease, amelioration of neoplastic disease, and cure of the neoplastic disease.
- the patient as referred to herein is a human patient, preferably a human cancer patient.
- compounds of the invention may be used to prevent or inhibit the progression of a cancer at various stages (e.g. tumor stage I, tumor stage II, tumor stage III, tumor stage IV) or treatment settings (e.g. preventative, adjuvant, neoadjuvant, therapeutic including palliative treatment).
- a compound of the invention may be for use in slowing, delaying or stopping cancer progression or cancer growth or increasing the overall survival time or the cancer-progression- free survival time or the time to progression of a cancer or improving or maintaining the patient's quality of life or functional status.
- the compounds according to formula I and pharmaceutically acceptable derivatives thereof may be used for the therapeutic treatment of neoplastic diseases.
- neoplastic diseases include, but are not limited to, epithelial neoplasms, squamous cell neoplasms, basal cell neoplasms, transitional cell papillomas and carcinomas, adenomas and adenocarcinomas, adnexal and skin appendage neoplasms, mucoepidermoid neoplasms, cystic neoplasms, mucinous and serous neoplasms, ducal-, lobular and medullary neoplasms, acinar cell neoplasms, complex epithelial neoplasms, specialized gonadal neoplasms, paragangliomas and glomus tumors, naevi and melanomas, soft tissue tumors and sarcomas, fibromatous neoplasms, myxomatous neoplasms, lipomatous neoplasms, myomatous
- the neoplastic disease is cancer.
- cancers in terms of the organs and parts of the body affected include, but are not limited to, the brain, breast, cervix, ovaries, colon, rectum, (including colon and rectum i.e.
- lung including small cell lung cancer, non-small cell lung cancer, large cell lung cancer and mesothelioma
- endocrine system bone, adrenal gland, thymus, liver, stomach, intestine, (including gastric cancer), pancreas, bone marrow, hematological malignancies, (such as lymphoma, leukemia, myeloma or lymphoid malignancies), bladder, urinary tract, kidneys, skin, thyroid, brain, head, neck, prostate and testis.
- malignancies such as lymphoma, leukemia, myeloma or lymphoid malignancies
- bladder urinary tract, kidneys, skin, thyroid, brain, head, neck, prostate and testis.
- the cancer is selected from the group consisting of brain cancer (e.g. glioblastoma), breast cancer (including triple negative breast cancer), prostate cancer, cervical cancer, ovarian cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung cancer, kidney cancer, hematological malignancies, melanoma and sarcomas.
- brain cancer e.g. glioblastoma
- breast cancer including triple negative breast cancer
- prostate cancer including triple negative breast cancer
- cervical cancer cervical cancer
- ovarian cancer gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung cancer, kidney cancer, hematological malignancies, melanoma and sarcomas.
- the cancer to be treated is a tumor, preferably a solid tumor.
- the neoplastic disease is a brain neoplasm, e.g. a brain tumor, which include but are not limited to glial- and non-glial-tumors, astrocytomas (incl.
- glioblastoma multiforme and unspecified gliomas oligodendrogliomas, ependydomas, menigiomas, haemangioblastomas, acoustic neuromas, craniopharyngiomas, primary central nervous system lymphoma, germ cell tumors, pituitary tumors, pineal region tumors, primitive neuroectodermal tumors (PNET's), medullablastomas, haemangiopericytomas, spinal cord tumors including meningiomas, chordomas and genetically- driven brain neoplasms including neurofibromatosis, peripheral nerve sheath tumors and tuberous sclerosis.
- brain neoplasm refers to glioblastomas (also referred to as glioblastoma multiforme).
- a compound of formula I or a pharmaceutically acceptable derivative thereof can be administered alone or in combination with one or more other therapeutic agents.
- Possible combination therapy may take the form of fixed combinations, or the administration of a compound of the invention and one or more other therapeutic agents which are staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic agents.
- a compound of formula I or a pharmaceutically acceptable derivative thereof can, besides or in addition, be administered especially for tumor therapy in combination with chemotherapy (cytotoxic therapy), 5 targeted therapy, endocrine therapy, biologies, radiotherapy, immunotherapy, surgical intervention, or a combination of these.
- chemotherapy cytotoxic therapy
- 5 targeted therapy endocrine therapy
- biologies endocrine therapy
- radiotherapy immunotherapy
- surgical intervention or a combination of these.
- Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above.
- Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemo-preventive therapy, for example in patients at risk.
- the compound referred to is preferably the compound of formula I-B and pharmaceutically acceptable salts thereof, and in particular dihydrochloride salt of the compound of formula I-B.
- BAL101553 dihydrochloride salt
- BAL101553 dihydrochloride salt
- BAL101553 dihydrochloride salt
- BALI 01553 (dihydrochloride salt) for intravenous administration is prepared by reconstitution of lyophilized BAL101553 (dihydrochloride salt) with saline solution or Ringer lactate solution, prior to further dilution with Ringer lactate for intravenous infusion to the patient.
- the 48-hour infusion is 35 administered via an elastomeric pump (Baxter) using an infusion volume of 120ml or 240ml.
- BAL101553 (dihydrochloride salt) for oral administration is prepared as a HPMC capsules containing 1 mg active ingredient, 98 mg of mannitol and 1 mg magnesium stearate, or 5 mg active ingredient, 94 mg mannitol and 1 mg magnesium stearate.
- MTD maximum tolerated dose
- the maximum tolerated dose (MTD) of the daily oral administration clinical trial described above was declared as 16 mg/day.
- Plasma concentrations of BAL27862 were determined with a fully 25 validated LC-MS/MS method:
- Detection was carried out using a triple-stage quadrupole MS/MS (TSQ Vantage, Thermo Fisher Scientific, San Jose, CA, USA) in the selected reaction monitoring mode.
- AUC and C max of BAL27862 were calculated by non-compartmental analysis (NCA) using Phoenix WinNonLin 7.0 software from Certara.
- Table 2 shows a comparison of the PK results and serious Grade 4 adverse drug reactions for BAL101553 administration by 48 hour continuous infusion versus daily oral administration. This data illustrate the safety and efficacy benefit of continuous infusion over daily oral administration of BAL101553 at comparable weekly pharmacokinetic exposure levels of BAL27862.
- the 48-hour dose regimen was furthermore associated with a lower variability of pharmacokinetic exposure (AUC).
- Grade 4 adverse events are generally defined as "Life-threatening consequences; OR urgent intervention indicated”.
- Grade 4 events are defined as hyponatremia that is life-threatening or characterized by sodium blood levels ⁇ 120mmol/L.
- CCAE Common Terminology Criteria for Adverse Events
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17171226 | 2017-05-16 | ||
PCT/EP2018/062601 WO2018210868A1 (en) | 2017-05-16 | 2018-05-15 | Novel dosage principle for drugs useful for treating neoplastic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3624790A1 true EP3624790A1 (en) | 2020-03-25 |
Family
ID=58709876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18722638.6A Withdrawn EP3624790A1 (en) | 2017-05-16 | 2018-05-15 | Novel dosage principle for drugs useful for treating neoplastic diseases |
Country Status (3)
Country | Link |
---|---|
US (1) | US11633383B2 (en) |
EP (1) | EP3624790A1 (en) |
WO (1) | WO2018210868A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102648947B1 (en) | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | Process for manufacturing furazanobenzimidazole and its crystalline form |
US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
US20220370418A1 (en) | 2019-09-09 | 2022-11-24 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004011515T2 (en) | 2003-05-23 | 2009-01-29 | Basilea Pharmaceutica Ag | FURAZANOBENZIMIDAZOLE |
MX336240B (en) | 2009-07-27 | 2016-01-13 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases. |
WO2012098208A1 (en) | 2011-01-21 | 2012-07-26 | Basilea Pharmaceutica Ag | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles |
US9995754B2 (en) | 2011-01-21 | 2018-06-12 | Basilea Pharmaceutica Ag | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |
ES2620582T3 (en) | 2011-01-21 | 2017-06-29 | Basilea Pharmaceutica Ag | Use of BUBR1 as a biomarker of the drug response to furazanobenzimidazoles |
PT2678679T (en) | 2011-02-24 | 2017-04-07 | Basilea Pharmaceutica Ag | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles |
PT2691533T (en) | 2011-03-29 | 2017-06-20 | Basilea Pharmaceutica Ag | Use of phospho-akt as a biomarker of drug response |
WO2015173341A1 (en) | 2014-05-13 | 2015-11-19 | Basilea Pharmaceutica Ag | Dosage principle for anti-cancer furazanylbenzimidazoles |
CN108139405B (en) | 2015-10-22 | 2022-06-10 | 巴斯利尔药物国际股份公司 | Use of EB1 as a biomarker of drug response |
KR102648947B1 (en) | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | Process for manufacturing furazanobenzimidazole and its crystalline form |
US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
-
2018
- 2018-05-15 EP EP18722638.6A patent/EP3624790A1/en not_active Withdrawn
- 2018-05-15 WO PCT/EP2018/062601 patent/WO2018210868A1/en unknown
- 2018-05-15 US US16/611,524 patent/US11633383B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018210868A1 (en) | 2018-11-22 |
US11633383B2 (en) | 2023-04-25 |
US20200237730A1 (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11633383B2 (en) | Dosage principle for drugs useful for treating neoplastic diseases | |
US10117945B2 (en) | mTORC1 inhibitors | |
JP6106228B2 (en) | Aqueous solutions containing 3-quinuclidinone for the treatment of hyperproliferative diseases, autoimmune diseases, and heart diseases | |
US20090069394A1 (en) | Cancer treatment with epothilones | |
KR20110009664A (en) | Method and compositions for treatment of cancer | |
US20170071903A1 (en) | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer | |
JP2014534238A (en) | Administration of bis (thiohydrazide amide) compounds to treat cancer | |
RU2358730C2 (en) | Epothilone derivative for treatment of hepatome and other cancer diseases | |
KR102466886B1 (en) | Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer | |
EP3713565A1 (en) | Pharmaceutical combinations for use in the treatment of neoplastic diseases | |
Thankan et al. | Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model | |
US20220031670A1 (en) | Pharmaceutical combinations for use in the treatment of neoplastic diseases | |
KR101851820B1 (en) | Therapeutic treatment | |
AU2004251444B2 (en) | Cancer treatment with epothilones | |
WO2024123297A2 (en) | Development of new docetaxel conjuged drug candidates to treat castration-resistant prostate cancer (crpc) | |
WO2018144791A1 (en) | Combination of vps34 inhibitors and mtor inhibitors | |
Ying | Discovery and Development of Ganetespib | |
Calleja | New chemotherapy approaches based on mucus-penetrating nanoparticles as carriers for paclitaxel | |
OA17078A (en) | New pediatric uses of cabazitaxel. | |
KR20110104932A (en) | Antitumor combination combining ave8062 and docetaxel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191216 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230915 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20240326 |